Anti-IL13 Neutralizing Antibody (V3S-0622-YC4585) (CAT#: V3S-0622-YC4585)

Send Inquiry
  • fig1
    Figure 1 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in ELISA
  • fig1
    Figure 2 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in WB
  • fig1
    Figure 3 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in DB

Datasheet

MSDS

COA

Summary
Property
Applications
Protocols
Target

Summary

Description This product is a human monoclonal antibody that reacts with IL13. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation.
Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free.
Clonality Monoclonal
Host Species Human
Target Species Human
Isotype IgG

Property

Expression Species HEK293F or CHO
Conjugation None
Purity >95%, determined by SDS-PAGE and/or SEC-HPLC
Endotoxin <1 EU/mg, determined by LAL method
Purification Protein A affinity purified
Sterility 0.2 μM filtered
Formulation PBS, pH 7.4
Preservation No preservatives
Stabilizer No stabilizers
Storage Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C.

Applications

Application WB; DB; FC; IP; ELISA; Neut; FuncS; IF; IHC
Application Notes The antibody is recommended for detection of IL13 by FC, IP, ELISA, Neut, FuncS, IF, IHC assays.

Protocols

ELISA Enzyme-Linked Immunosorbent Assay Protocol
WB Western Blot Protocol
FC Flow Cytometry Protocol

Target

Target IL13
Alternative Name IL13; interleukin 13; P600; IL-13; interleukin-13
Gene ID 3596
UniProt P35225
Research Area Cardiovascular; Immunology

Tested Data

ELISA

Figure 1 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in ELISA

ELISA analysis of V3S-0622-YC4585 was performed by coating with Recombinant Human IL13. Then blocked with BSA and incubated with V3S-0622-YC4585. The HRP-conjugated goat anti- human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 1 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in ELISA

WB

Figure 2 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in WB

WB analysis of V3S-0622-YC4585 was performed by loading with Recombinant Human IL13 onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC4585 and HRP goat anti-human IgG (H+L) as a secondary antibody (1: 3000). Chemiluminescent detection was performed.

Figure 2 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in WB

DB

Figure 3 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in DB

DB analysis of V3S-0622-YC4585 was performed by coating with Recombinant Human IL13.

V3S-0622-YC4585 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG (H+L) as a secondary antibody (1: 3000)
NC: Negative control, PC: Positive control

Figure 3 Anti-Human IL13 Monoclonal Antibody (V3S-0622-YC4585) in DB

For research use only, not directly for clinical use.
banner banner
© 2024 Creative Biolabs. All Rights Reserved.
antibody
Online Inquiry